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Description

COVID-19 is a new coronavirus that can cause severe respiratory distress. Interestingly,
patients can present with COVID-19 and appear relatively well but with significant hypoxia,
even with minimal movement. The authors present the case of a well-appearing gentleman
who became acutely short of breath while undergoing chest imaging, stating he could not
breathe. He tested positive for COVID-19 and recovered. His presentation, clinical course and
imaging findings are discussed.
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Introduction

An outbreak of pneumonia associated with a
novel coronavirus, now commonly known as
COVID-19, emerged in Wuhan, China, in December 2019. For most of 2020, this novel virus
that had been causing severe illness globally,
becoming a pandemic—an outcome that has
not been seen since the Spanish Flu of 1918.1
Typically, patients with COVID-19 pneumonia present with fever, shortness of breath,
non-productive cough and fatigue.2 Some are
extremely ill, with acute respiratory distress
requiring mechanical ventilation. However,
some patients can present with COVID looking
relatively well while at rest, with respiratory
distress only occurring with exertion, even only
minimal exertion. The authors present such a
case. The patient came in with a history that
was consistent with pneumonia. He appeared
relatively well as long as he did not have to
speak, move or hold his breath. Even minimal
exertion dropped his oxygen saturation precipitously.

Case Presentation

A 61-year-old male presented to our emergency
department with the chief complaint of cough

and fever that had been gradually worsening
over the last 10 days since admission to the
hospital. The patient reported no medical problems and denied any medication use on a daily
basis. The patient did not smoke, drink or use
drugs of any kind. He stated he was unable to
take a deep breath without significant amounts
of coughing and that it took him several seconds to breathe more easily. He reported having a fever at home that did not improve with
antipyretics. He also reported a mild headache.
On the physical exam, the patient was tachypneic with a respiratory rate of 27 breaths/
minute. While he was giving his history, his
oxygen saturation went from 99% on room air
down to 90%. It took greater than 10 seconds
for his oxygen saturation to return to normal
after he finished speaking. He was febrile, with
a temperature of 100.8°F. His blood pressure
was 173/82 mm Hg, and his pulse was 103 beats
per minute. The exam was also indicative of a
dry cough.
Given his fever and tachypnea, an initial workup
for sepsis was ordered. Results demonstrated
typical mild lymphopenia, elevated D-dimer
and elevated procalcitonin. His labs were other-
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wise unremarkable. Chest radiograph demonstrated multilobar pneumonia. (Figure 1) His
chest computed tomography demonstrated
ground-glass opacities noted throughout the
lungs, most prominent in the right upper lobe
and left lower lobe. (Figure 2)
Etiologies such as atypical pneumonia, organizing pneumonia and malignancy were considered, but given the patient’s clinical picture,
COVID-19 was at the top of our differential.
The patient was placed in respiratory isolation
and subsequently admitted for further testing, treatment and observation. Throughout
his emergency department stay, the patient
remained stable without evidence of impending deterioration as long as he did not exert
himself—even minimal movement caused him
to desaturate. The patient’s COVID-19 test
then came back positive. He was treated with
1 g ceftriaxone IV, 500 mg azithromycin IV in
the ED and 1 oral dose of ivermectin 16.5 mg
inpatient. The patient’s clinical course never
significantly deteriorated. He did not require
intubation or ventilatory support. He was
discharged on hospital day 14 with ambulatory
room air saturation of 94% and normal labs. He
was instructed to strictly quarantine himself
for another 14 days.

Discussion

There are currently 7 types of coronaviruses
that infect humans, 4 of which generally cause
mild, self-limited illnesses of the upper respiratory and gastrointestinal tracts.3,4 In 2002,
Severe Acute Respiratory Syndrome, caused
by the coronavirus SARS-CoV, swept across
Guangdong, China, resulting in over 700 fatalities.5 Common symptoms include fever, myalgias, headache, nonproductive cough, dyspnea
and, in 30-40% of cases, diarrhea.4 Middle East
Respiratory Syndrome coronavirus (MERSCoV) was first detected in Saudi Arabia and resulted in over 800 deaths.4 Spread by zoonotic
transmission, specifically by camels, MERS
commonly presents with similar symptoms as
SARS but has also been noted to cause sore
throat, pneumonia, vomiting and acute renal
impairment. Fatality rates for SARS and MERS
have been reported as 9% and 36%, respectively.4
As the COVID-19 coronavirus has an 82% nucleotide match with SARS-CoV, it was named
SARS-CoV-2. An estimated 81% of patients will
have a mild flu-like illness. Our patient presented with the frequently reported symptoms
of fever, cough and dyspnea.6 Severe disease
will develop in 5% of patients, including acute
respiratory distress syndrome (ARDS), septic

Figure 1. Chest radiograph demonstrating multifocal pneumonia (arrows).
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Figure 2. Bilateral ground glass opacities (arrows) on chest computed tomography (CT).
shock and respiratory failure requiring mechanical ventilation.5 Mortality rates early in the
pandemic were noted to be as high as 11–15%,
as patients who died had developed ARDS and
multi-organ failure over a short period of time.
Later reports note rates closer to 2–3%.7
The most common laboratory findings in
patients include decreased albumin, elevated
C-reactive protein, elevated lactate dehydrogenase and lymphopenia.8 CT chest findings
in COVID-19 patients demonstrate bilateral
ground glass opacities—most likely peripheral—
initially and progress to multilobar consolidations.9,10 The patient presented in this case had
the typical laboratory and chest CT findings for
COVID-19.
Several medications are under investigation
as treatment for COVID-19. On August 23rd,
2020, the U.S. Food and Drug Administration
issued an emergency use authorization (EUA)
for a COVID-19 convalescent plasma that is
believed to reduce the duration of the illness
and minimize the severity.11 Remdesivir also
proves to be a promising medication at this
time.7 Hydroxychloroquine has been among the
most investigative treatment options. However, its efficacy has been doubted recently, and
its side effect profile, mainly QT prolongation
causing arrhythmias, makes this drug less
desirable.12 Convalescent plasma transfusion
with neutralizing antibodies has been shown
to result in significant clinical improvement in

select patients with ARDS and is currently still
under investigation.13 Ivermectin is an anthelmintic agent that has been safely used for
decades, and a consensus panel deemed it safe
to use for any severity of COVID-19.14 It works
via selective inhibition of the host importin α/β
transporter protein, which decreases translocation of SARS-CoV nucleocapsid protein
from the cytoplasm to the nucleus. This altered
nucleocapsid protein distribution disrupts viral
propagation and survival.15
In our area, Orlando, Florida, new cases of
COVID-19 have been erratically fluctuating
every day, but there is no noticeable increase
or decrease in the trend of cases over time. On
September 8th, 2020, there were 2,324 new
cases presented, but, in comparison, 1 month
later, there were 2,904 new cases on October
8th, 2020.16 The lowest number of new cases
a day in Orlando, which was 810, occurred on
September 27th, 2020. However, there are no
distinguishable attributes over the course of
the time period that explains why there were
significantly less new cases that day.

Conclusion

Our patient presented with the commonly reported symptoms of fever, cough and dyspnea.
On presentation, he was approximately 10 days
into his illness, which was in the moderate to
severe stage given his tachypnea and significant drop in oxygen saturation with minimal
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exertion. Fortunately, he did not require mechanical ventilator support and was discharged
from the hospital 14 days later. Although most
patients will have mild symptoms, a significant number will develop severe disease, which
can rapidly progress to respiratory failure and
death.
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